ReShape Lifesciences Enters Material Definitive Agreement

TL;DR

ReShape Lifesciences signed a big deal on Jan 14, 2025.

AI Summary

On January 14, 2025, ReShape Lifesciences Inc. entered into a material definitive agreement. The company, formerly known as Obalon Therapeutics Inc., is incorporated in Delaware and headquartered in San Clemente, California.

Why It Matters

This filing indicates a significant new contract or partnership for ReShape Lifesciences, which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: medium — The nature of the material definitive agreement is not specified, leaving uncertainty about its terms and potential impact.

Key Players & Entities

• ReShape Lifesciences Inc. (company) — Registrant
• Obalon Therapeutics Inc. (company) — Former company name
• January 14, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• San Clemente, California (location) — Business address

FAQ

Key Financial Figures

• $0.001 — nge on which Registered Common stock, $0.001 par value per share RSLS The Nasdaq C
• $833,333.34 — aggregate original principal amount of $833,333.34 (the "Note"). On January 14, 2025, the
• $45,000 — ings from 66% to 50%, and (d) require a $45,000 cash extension fee to be paid by the Co

Filing Documents

• tm253570d3_8k.htm (8-K) — 28KB
• tm253570d3_ex10-1.htm (EX-10.1) — 31KB
• tm253570d3_ex10-1img001.jpg (GRAPHIC) — 3KB
• 0001104659-25-004884.txt ( ) — 238KB
• rsls-20250114.xsd (EX-101.SCH) — 3KB
• rsls-20250114_lab.xml (EX-101.LAB) — 33KB
• rsls-20250114_pre.xml (EX-101.PRE) — 22KB
• tm253570d3_8k_htm.xml (XML) — 3KB

01

Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed, on October 16, 2024, ReShape Lifesciences Inc. (the "Company") entered into a securities purchase agreement (the "SPA") with Ascent Partners Fund LLC, an institutional investor (the "Investor"). Pursuant to the SPA, among other things, the Company agreed to issue the Investor a senior secured convertible note in the aggregate original principal amount of $833,333.34 (the "Note"). On January 14, 2025, the Company entered into an amendment to the Note (the "Amendment") with the Investor to (a) extend the maturity date to the earlier of (i) the closing of the Company's previously announced merger with Vyome Therapeutics, Inc. (the "Merger") or (ii) 90 days after the date of the Amendment, (b) provide that the Investor would not be obligated to convert any part of the Note at the closing of the Merger, (c) reduce the mandatory prepayment provision for funds raised by the Company in subsequent financings from 66% to 50%, and (d) require a $45,000 cash extension fee to be paid by the Company at the maturity of the Note. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by the terms and conditions of the Amendment filed as Exhibit 10.1 hereto and incorporated by reference herein.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Amendment to Form of Note, dated as of January 14, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RESHAPE LIFESCIENCES INC. By: /s/ Paul F. Hickey Paul F. Hickey Chief Executive Officer Dated: January 21, 2025

View Full Filing

View this 8-K filing on SEC EDGAR